Neurodesarrollo en pacientes con retinopatia del prematuro. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext. Systemic whole body safety of bevacizumab versus ranibizumab for neovascular agerelated macular degeneration. Bevacizumab is a recombinant humanized monoclonal antibody to vegf.
Profile of bevacizumab and its potential in the treatment of cervical cancer. Background neovascular agerelated macular degeneration amd is a progressive and chronic disease of the eye, and a leading cause of. Developing nations are targeting improvements in systemic therapy for cervical cancer to improve the lives of young mothers. Insuficiencia cardiaca refractaria en paciente tratada con bevacizumab. Systemic safety of bevacizumab versus ranibizumab for. Highlights of prescribing information platinumresistant. Bevacizumab hta perforaciones yo sangrado gastrointestinal proteinuria estabilidad m. Oct 19, 2015 2015 10 actualizacion bevacizumab pulmon 1. Profile of bevacizumab and its potential in the treatment of. Bevacizumab represents a novel therapeutic strategy targeting the vascular endothelial growth factor vegf pathway. Refractory heart failure in a patient treated with bevacizumab. Cervical cancer diagnoses in the us,1 and worldwide,2 continues to be a major cause of morbidity and mortality among young women.
1397 602 815 878 762 1374 195 465 1156 1306 41 718 1301 826 795 598 1487 822 18 355 791 805 303 352 458 931 1260 484 1170 636 1096 1278 382 1284 1319 729 1263 1241 185 979 1085 306 675 977 1054 47 910